[The therapeutic effects of FLAG regime for refractory and relapsing acute leukemia].

Abstract

OBJECTIVE:

To investigate the therapeutic effects of FLAG regimen for refractory and relapsing acute leukemia.

METHODS:

Fludarabine 30 mg.m(-2).d(-1), 3 - 5 days, Ara-C 1.5 g.m(-2).d(-1), 5 d and, G-CSF 5 microg.kg(-1).d(-1) were used to treat 7 cases (10 times) of refractory and relapsed leukemia.

RESULTS:

Of the 10 times, nine showed response to therapy; one case died of complication. Neutropenia begin at the time of 5 - 12 days after the regimen initiating and last 5 - 34 days, thrombocytopenia begin at 5 - 18 days and last 5 - 36 days. The adverse reaction includes hyperamino transferase, pyrexia and diarrhea.

CONCLUSION:

FLAG shows obvious effects for refractory and relapsing acute leukemia and gains time for hematopoietic stem cell transplantation.

• Authors: Xiao-jun Huang, Jin Lu, Dao-pei Lu
• Journal: Zhonghua nei ke za zhi (Zhonghua Nei Ke Za Zhi) Vol. 42 Issue 6 Pg. 417-9 (Jun 2003) ISSN: 0578-1426 [Print] China
• PMID: 12895328 (Publication Type: English Abstract, Journal Article)

Chemical References

• Cytarabine
• Granulocyte Colony-Stimulating Factor
• Vidarabine

Topics

• Acute Disease
• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Cytarabine (administration & dosage)
• Drug Administration Schedule
• Female
• Granulocyte Colony-Stimulating Factor (administration & dosage)
• Humans
• Leukemia (drug therapy)
• Male
• Middle Aged
• Recurrence
• Vidarabine (administration & dosage, analogs & derivatives)